← Leaderboards
Harry H Yoon
Mayo Clinic Rochester
$3,119,133
Attributed
$3,119,133
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $640.2K · FY2021–25$1M$750K$500K$250K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,119,133 · 1
By mechanism
R01$3,119,133 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Yi Lin$6,996,175
- Hu Zeng$3,944,442
- Sujit Basu$9,062,631
- Carmen M Terzic$1,881,195
- Luke Hilbert Hoeppner$878,191
Others in their field
Other Emerging Leaders on “Disease Progression”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Beth Baseler · Leidos Biomedical Research, Inc.$111,936,677
- Klaus Romero · Critical Path Institute$90,404,592
- Susan Abushakra · Alzheon, Inc.$47,265,244
- John Damon Chodera · Sloan-Kettering Inst Can Research$45,424,821
- Ryan Cirz · Revagenix, Inc.$40,209,479
Research focus
Disease ProgressionDesignAntineoplastic AgentsAntiangiogenesis TherapyAnti-Tumor Immune ResponseAftercareBevacizumabBiologicalBlood SpecimenCancer EtiologyCancer TherapyCause Of DeathCd8-Positive T-LymphocytesCessation Of LifeChemotherapyClinical EfficacyClinical TrialsCombination ImmunotherapyCombined Modality TherapyCytometryCytotoxic AgentCytotoxic ChemotherapyDensityDistant Metastasis
Grant awards (5)
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer$627,404
R01 · FY2025 · CA · contact PI
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer$591,765
R01 · FY2024 · CA · contact PI
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer$620,514
R01 · FY2023 · CA · contact PI
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer$639,268
R01 · FY2022 · CA · contact PI
Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancer$640,182
R01 · FY2021 · CA · contact PI